Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Addex Therapeutics (ADXN) FCF Margin: 2022-2024

Historic FCF Margin for Addex Therapeutics (ADXN) over the last 3 years, with Dec 2024 value amounting to 354,774,046,846.55%.

  • Addex Therapeutics' FCF Margin rose 34997161479489.00% to 354,774,046,846.55% in Q4 2024 from the same period last year, while for Dec 2024 it was -14,792,780.22%, marking a year-over-year decrease of 1853376804.00%. This contributed to the annual value of -1,330.07% for FY2024, which is 83413.00% down from last year.
  • Addex Therapeutics' FCF Margin amounted to 354,774,046,846.55% in Q4 2024, which was up 3,670.09% from -9,937,390,732.37% recorded in Q3 2024.
  • Over the past 5 years, Addex Therapeutics' FCF Margin peaked at 354,774,046,846.55% during Q4 2024, and registered a low of -9,937,390,732.37% during Q3 2024.
  • Moreover, its 3-year median value for FCF Margin was -1,381.40% (2024), whereas its average is 29,011,730,013.51%.
  • Data for Addex Therapeutics' FCF Margin shows a peak YoY increase of 34,997,161,479,489bps (in 2024) and a maximum YoY decrease of 925,020,726,290bps (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Addex Therapeutics' FCF Margin stood at -518.51% in 2022, then surged by 480,243,257,017bps to 4,802,432,051.66% in 2023, then spiked by 34,997,161,479,489bps to 354,774,046,846.55% in 2024.
  • Its last three reported values are 354,774,046,846.55% in Q4 2024, -9,937,390,732.37% for Q3 2024, and -2,835.56% during Q2 2024.